Graves' ophthalmopathy and tobacco smoking

1993 ◽  
Vol 129 (2) ◽  
pp. 147-150 ◽  
Author(s):  
Leif Tallstedt ◽  
Göran Lundell ◽  
Adam Taube
Keyword(s):  
Risk Factor ◽  
Tobacco Smoking ◽  
Statistical Significance ◽  
Smoking Habits ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Graves Ophthalmopathy ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies

We have studied the smoking habits in a group of patients with hyperthyroidism caused by Graves' disease. One hundred and seventy-one patients were randomized to different forms of treatment for hyperthyroidism and the outcome of this study concerning Graves' ophthalmopathy has been described previously. There were 89 smokers (52%) and 82 non-smokers (48%). Among the smokers there were 32 patients (19%) who developed ophthalmopathy or deteriorated in an already present ophthalmopathy and 57 patients who did not (33%), whereas among the non-smokers, 14 (8%) had ophthalmopathy during the study and 68 (40%) did not (p =0.006). We could not obtain statistical significance when trying to demonstrate that smoking is a risk factor for the development of ophthalmopathy after treatment for hyperthyroidism. It was noted that smokers had higher pretreatment levels of thyrotropin-receptor antibodies (p = 0.027). In conclusion, these results support the previously described association between smoking and Graves' ophthalmopathy.

scholarly journals Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease

2019 ◽  
Vol 105 (4) ◽  
pp. e1006-e1014 ◽  
Author(s):  
George J Kahaly ◽  
Tanja Diana ◽  
Michael Kanitz ◽  
Lara Frommer ◽  
Paul D Olivo
Keyword(s):  
Predictive Value ◽  
Prospective Trial ◽  
Thyroid Stimulating Hormone ◽  
Luciferase Expression ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Tertiary Referral Center ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies

Abstract Context Scarce data exist regarding the relevance of stimulatory (TSAb) and blocking (TBAb) thyrotropin receptor antibodies in the management of Graves disease (GD). Objective To evaluate the clinical utility and predictive value of TSAb/TBAb. Design Prospective 2-year trial. Setting Academic tertiary referral center. Patients One hundred consecutive, untreated, hyperthyroid GD patients. Methods TSAb was reported as percentage of specimen-to-reference ratio (SRR) (cutoff SRR < 140%). Blocking activity was defined as percent inhibition of luciferase expression relative to induction with bovine thyrotropin (TSH, thyroid stimulating hormone) alone (cutoff > 40% inhibition). Main Outcome Measures Response versus nonresponse to a 24-week methimazole (MMI) treatment defined as biochemical euthyroidism versus persistent hyperthyroidism at week 24 and/or relapse at weeks 36, 48, and 96. Results Forty-four patients responded to MMI, of whom 43% had Graves orbitopathy (GO), while 56 were nonresponders (66% with GO; P < 0.01). At baseline, undiluted serum TSAb but not thyroid binding inhibitory immunoglobulins (TBII) differentiated between thyroidal GD-only versus GD + GO (P < 0.001). Furthermore, at baseline, responders demonstrated marked differences in diluted TSAb titers compared with nonresponders (P < 0.001). During treatment, serum TSAb levels decreased markedly in responders (P < 0.001) but increased in nonresponders (P < 0.01). In contrast, TBII strongly decreased in nonresponders (P = 0.002). All nonresponders and/or those who relapsed during 72-week follow-up period were TSAb-positive at week 24. A shift from TSAb to TBAb was noted in 8 patients during treatment and/or follow-up and led to remission. Conclusions Serum TSAb levels mirror severity of GD. Their increase during MMI treatment is a marker for ongoing disease activity. TSAb dilution analysis had additional predictive value.

scholarly journals Second Generation Assay for Thyrotropin Receptor Antibodies Has Superior Diagnostic Sensitivity for Graves’ Disease

1999 ◽  
Vol 84 (1) ◽  
pp. 90-97 ◽  
Author(s):  
Sabine Costagliola ◽  
Nils G. Morgenthaler ◽  
Rudolf Hoermann ◽  
Klaus Badenhoop ◽  
Joachim Struck ◽  
...  
Keyword(s):  
Second Generation ◽  
Diagnostic Sensitivity ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies

The Prevalence and Clinical Significance of Blocking Thyrotropin Receptor Antibodies in Untreated Hyperthyroid Graves' Disease

Thyroid ◽  
2000 ◽  
Vol 10 (7) ◽  
pp. 579-586 ◽  
Author(s):  
Won Bae Kim ◽  
Hyun Kyung Chung ◽  
Young Joo Park ◽  
Do Joon Park ◽  
Kazuo Tahara ◽  
...  
Keyword(s):  
Clinical Significance ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies

scholarly journals Thyrotropin Receptor Antibodies and Graves’ Disease, a Side-Effect of131I Treatment in Patients with Nontoxic Goiter1

1997 ◽  
Vol 82 (9) ◽  
pp. 2926-2930 ◽  
Author(s):  
Birte Nygaard ◽  
Jens Helmer Knudsen ◽  
Laszlo Hegedüs ◽  
Annegrete Veje Cand Scient ◽  
Jens Erik Mølholm Hansen
Keyword(s):  
Side Effect ◽  
Graves Disease ◽  
Thyrotropin Receptor ◽  
Thyrotropin Receptor Antibodies ◽  
Receptor Antibodies
Sign in / Sign up

Export Citation Format

Share Document